NY Times: Medicaid work requirements don’t work if beneficiaries aren’t aware

Since the Trump administration began allowing states to implement work requirements within their Medicaid programs, thousands of beneficiaries have been impacted, with some already losing critical healthcare coverage. Unfortunately, as more of these programs roll out, not all beneficiaries will be able to meet the requirements–simply because they aren’t aware of them, according to The New York Times.

Arkansas, the first state to implement work requirements, saw 4,300 people lose their benefits by the third month of the new rules as a result of noncompliance. More are likely to lose coverage in the coming months.

The low compliance figures suggest that many Medicaid beneficiaries may not have been aware the program existed, despite state efforts to get the word out through letters, emails, phone calls and more. But many people didn’t open their mail or answer phone calls, the NY Times reported. In addition, Arkansas’ requirements meant people could only report the hours they worked online, and the state has one of the nation’s lowest internet penetration rates.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.